

1 ***Extracellular cysteine disulfide bond break at Cys122 disrupts PIP<sub>2</sub>-dependent Kir2.1***  
2 ***channel function and leads to arrhythmias in Andersen-Tawil Syndrome***  
3

4 Francisco M. Cruz, PhD<sup>1,\*</sup>, Álvaro Macías, PhD<sup>1</sup>, Ana I. Moreno-Manuel, MSc<sup>1</sup>, Lilian K.  
5 Gutiérrez, MSc<sup>1</sup>, María Linarejos Vera-Pedrosa, MSc<sup>1</sup>, Isabel Martínez-Carrascoso, MSc<sup>1</sup>,  
6 Patricia Sánchez Pérez, PhD<sup>1</sup>, Juan Manuel Ruiz Robles, MSc<sup>1</sup>, Francisco J Bermúdez-  
7 Jiménez, MD, PhD<sup>1,4,6</sup>, Aitor Díaz-Agustín, PhD,<sup>9</sup> Fernando Martínez de Benito, PhD<sup>1,2</sup>,  
8 Salvador Arias Santiago, MD, PhD<sup>5,6</sup> Aitana Braza-Boils, PhD<sup>7,8</sup>, Mercedes Martín-Martínez,  
9 PhD<sup>9</sup>, Marta Gutierrez-Rodríguez, PhD<sup>9</sup>, Juan A. Bernal, PhD,<sup>1,2</sup> Esther Zorio,<sup>2,7,8</sup> MD, Juan  
10 Jiménez-Jaimez, MD<sup>4,6</sup>, José Jalife, MD, PhD<sup>1,2,3,\*</sup>.

11  
12 <sup>1</sup>Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain;

13 <sup>2</sup>CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain;

14 <sup>3</sup>Departments of Medicine and Molecular & Integrative Physiology, University of Michigan,  
15 Ann Arbor, MI, USA.

16 <sup>4</sup>Servicio de Cardiología, Hospital Universitario Virgen de las Nieves, Granada, Spain

17 <sup>5</sup>Servicio de Dermatología Hospital Universitario Virgen de las Nieves

18 <sup>6</sup>Instituto de Investigación Biosanitaria de Granada IBS, Granada, Spain

19 <sup>7</sup>Unit of Inherited Cardiomyopathies and Sudden Death (CAFAMUSME), Health Research  
20 Institute La Fe, La Fe Hospital, Valencia, Spain

21 <sup>8</sup>Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain

22 <sup>9</sup>Instituto de Química Médica (IQM), Consejo Superior de Investigaciones Científicas (CSIC),  
23 28006 Madrid, Spain;

24  
25 **Short Title:** C122Y disrupts Kir2.1-PIP2 interaction in ATS1

26  
27 \*Corresponding authors:

28 José Jalife, MD, PhD.

29 Cardiac Arrhythmia Laboratory

30 Centro Nacional de Investigaciones Cardiovasculares (CNIC)

31 Melchor Fernández Almagro 3, 28029 Madrid, Spain

32 Email: [jjalife@cnic.es](mailto:jjalife@cnic.es)

33 Telephone: +34-91 453 12 00 (Ext. 1512)

34 FAX: +34-91 453 12 65

35  
36 Francisco Miguel Cruz, PhD.

37 Cardiac Arrhythmia Laboratory

38 Centro Nacional de Investigaciones Cardiovasculares (CNIC)

39 Melchor Fernández Almagro 3, 28029 Madrid, Spain

40 Email: [fmacruz@cnic.es](mailto:fmacruz@cnic.es)

41 Telephone: +34-91 453 12 00

42 FAX: +34-91 453 12 65

43  
44 **Keywords:** Ion channel diseases, Kir2.1-PIP<sub>2</sub> interaction, Arrhythmias, Sudden Cardiac  
45 Death, Molecular Dynamics

46  
47  
48  
49 **Total word count: 8608**

50 **Abstract**

51 **Background:** Andersen-Tawil Syndrome Type 1 (ATS1) is a rare heritable disease caused  
52 by mutations in the strong inwardly rectifying K<sup>+</sup> channel Kir2.1. The extracellular Cys122-to-  
53 Cys154 disulfide bond in the Kir2.1 channel structure is crucial for proper folding, but has not  
54 been associated with correct channel function at the membrane. We tested whether a human  
55 mutation at the Cys122-to-Cys154 disulfide bridge leads to Kir2.1 channel dysfunction and  
56 arrhythmias by reorganizing the overall Kir2.1 channel structure and destabilizing the open  
57 state of the channel.

58

59 **Methods and Results:** We identified a Kir2.1 loss-of-function mutation in Cys122 (c.366  
60 A>T; p.Cys122Tyr) in a family with ATS1. To study the consequences of this mutation on  
61 Kir2.1 function we generated a cardiac specific mouse model expressing the Kir2.1<sup>C122Y</sup>  
62 mutation. Kir2.1<sup>C122Y</sup> animals recapitulated the abnormal ECG features of ATS1, like QT  
63 prolongation, conduction defects, and increased arrhythmia susceptibility. Kir2.1<sup>C122Y</sup> mouse  
64 cardiomyocytes showed significantly reduced inward rectifier K<sup>+</sup> (I<sub>K1</sub>) and inward Na<sup>+</sup> (I<sub>Na</sub>)  
65 current densities independently of normal trafficking ability and localization at the  
66 sarcolemma and the sarcoplasmic reticulum. Kir2.1<sup>C122Y</sup> formed heterotetramers with  
67 wildtype (WT) subunits. However, molecular dynamic modeling predicted that the Cys122-  
68 to-Cys154 disulfide-bond break induced by the C122Y mutation provoked a conformational  
69 change over the 2000 ns simulation, characterized by larger loss of the hydrogen bonds  
70 between Kir2.1 and phosphatidylinositol-4,5-bisphosphate (PIP<sub>2</sub>) than WT. Therefore,  
71 consistent with the inability of Kir2.1<sup>C122Y</sup> channels to bind directly to PIP<sub>2</sub> in bioluminescence  
72 resonance energy transfer experiments, the PIP<sub>2</sub> binding pocket was destabilized, resulting  
73 in a lower conductance state compared with WT. Accordingly, on inside-out patch-clamping  
74 the C122Y mutation significantly blunted Kir2.1 sensitivity to increasing PIP<sub>2</sub> concentrations.

75

76 **Conclusion:** The extracellular Cys122-to-Cys154 disulfide bond in the tridimensional Kir2.1  
77 channel structure is essential to channel function. We demonstrated that ATS1 mutations  
78 that break disulfide bonds in the extracellular domain disrupt PIP<sub>2</sub>-dependent regulation,  
79 leading to channel dysfunction and life-threatening arrhythmias.

80

81 **Keywords:** Ion channel diseases, Kir2.1-PIP<sub>2</sub> interaction, Arrhythmias, Sudden Cardiac  
82 Death, Molecular Dynamics

83 **CLINICAL PERSPECTIVE**

84 **NOVELTY AND SIGNIFICANCE**

85 **What is known?**

- 86 • Andersen-Tawil Syndrome Type 1 (ATS1) is a rare arrhythmogenic disease caused  
87 by loss-of-function mutations in *KCNJ2*, the gene encoding the strong inward rectifier  
88 potassium channel Kir2.1 responsible for  $I_{K1}$ .
- 89 • Extracellular Cys<sub>122</sub> and Cys<sub>154</sub> form an intramolecular disulfide bond that is essential  
90 for proper Kir2.1 channel folding but not considered vital for channel function.
- 91 • Replacement of Cys<sub>122</sub> or Cys<sub>154</sub> residues in the Kir2.1 channel with either alanine or  
92 serine abolished ionic current in *Xenopus laevis* oocytes.

93 **What new information does this article contribute?**

- 94 • We generated a mouse model that recapitulates the main cardiac electrical  
95 abnormalities of ATS1 patients carrying the C122Y mutation, including prolonged QT  
96 interval and life-threatening ventricular arrhythmias.
- 97 • We demonstrate for the first time that a single residue mutation causing a break in  
98 the extracellular Cys<sub>122</sub>-to-Cys<sub>154</sub> disulfide-bond leads to Kir2.1 channel  
99 dysfunction and arrhythmias in part by reorganizing the overall Kir2.1 channel  
100 structure, disrupting PIP2-dependent Kir2.1 channel function and destabilizing the  
101 open state of the channel.
- 102 • Defects in Kir2.1 energetic stability alter the functional expression of the voltage-  
103 gated cardiac sodium channel Nav1.5, one of the main Kir2.1 interactors in the  
104 macromolecular channelosome complex, contributing to the arrhythmias.
- 105 • The data support the idea that susceptibility to arrhythmias and SCD in ATS1 are  
106 specific to the type and location of the mutation, so that clinical management should  
107 be different for each patient.
- 108 • Altogether, the results may lead to the identification of new molecular targets in the  
109 future design of drugs to treat a human disease that currently has no defined therapy.

## 110 Introduction

111 Andersen-Tawil syndrome type 1 (ATS1) is a rare, inheritable autosomal dominant  
112 disease caused by loss-of-function mutations in the *KCNJ2* gene, which codes the strong  
113 inward rectifier potassium channel Kir2.1.<sup>1,2</sup> Kir2.1 is ubiquitously expressed throughout the  
114 human body and ATS1 mutations predispose patients to a triad of alterations including  
115 periodic paralysis, dysmorphias, and arrhythmias that can lead to sudden cardiac death  
116 (SCD)<sup>3,4</sup> by mechanisms that remain unclear.<sup>5</sup> In the heart, Kir2.1 is responsible for the  
117 inward rectifier K<sup>+</sup> current ( $I_{K1}$ ),<sup>6</sup> which plays a central role in the maintenance of the resting  
118 membrane potential (RMP) and the final phase of action potential (AP) repolarization.<sup>7</sup>  
119 Therefore, loss-of-function mutations in Kir2.1 lead to a substantial decrease in  $I_{K1}$ , with  
120 consequent membrane depolarization at rest, as well as AP duration (APD) and QT interval  
121 prolongation.<sup>8</sup> Normal Kir2.1 channel function requires agonist phosphatidylinositol-4, 5-  
122 bisphosphate (PIP<sub>2</sub>) interactions, which stabilizes the G-loop in the open state. Defects in  
123 PIP<sub>2</sub> binding are a major pathophysiologic mechanism underlying the loss-of-function  
124 phenotype for several ATS1 associated mutations.<sup>5,9-11</sup>

125 The primary structure of the human Kir2.1 channel comprises a total of thirteen  
126 cysteine (Cys) residues distributed along each monomer. Cys residues are uniquely reactive  
127 providing the ability to form disulfide bonds.<sup>12</sup> They contribute to the structural stability of  
128 proteins while being key target sites for redox related processes.<sup>13</sup> Thus, Cys mutations may  
129 affect the tridimensional structure of the channel and alter its function. Seven Cys are  
130 expected to be distributed in the Kir2.1 channel N- and C-terminus regions, but mutation in  
131 most of them have not been shown to significantly affect the single-channel conductance nor  
132 the channel open probability.<sup>14</sup> However, mutating Cys<sub>76</sub> and Cys<sub>311</sub> to polar or charged  
133 residues modulated the interaction between Kir2.1 and PIP<sub>2</sub>, and resulted in either an  
134 absence of channel activity or a decrease in open probability.<sup>14</sup> Similarly, class Ic  
135 antiarrhythmic drugs have been shown to bind to the Cys<sub>311</sub> residue of the Kir2.1 channel,  
136 and to reduce the polyamine-induced inward rectification increasing the outward  $I_{K1}$ .<sup>15,16</sup> Four  
137 Cys residues are located in the channel transmembrane segment TM1 (Cys<sub>89</sub> and Cys<sub>101</sub>),  
138 the pore (Cys<sub>149</sub>) and TM2 regions (Cys<sub>169</sub>). Importantly, the remaining two Cys, Cys<sub>122</sub> and

139 Cys<sub>154</sub>, are located at extracellular space positions absolutely conserved across the inward  
140 rectifier family,<sup>17</sup> and form a disulfide bond crucial for channel assembly.<sup>12,18,19</sup> However, the  
141 Cys122-to-Cys154 disulfide bridge has not been considered essential for normal Kir2.1  
142 function once the channel has been formed.<sup>12</sup>

143 Here we report on an ATS1 family with a novel Kir2.1 loss-of-function mutation in  
144 Cys<sub>122</sub> (c.366 A>T; p.Cys122Tyr) (C122Y) with a high prevalence for ventricular arrhythmias,  
145 which in the case of the proband required implantation of an intracardiac defibrillator (ICD).  
146 To study the molecular mechanisms underlying life-threatening arrhythmias produced by the  
147 Kir2.1<sup>C122Y</sup> mutation, we generated a mouse model of ATS1 using adeno-associated virus  
148 (AAVs) Kir2.1<sup>C122Y</sup> gene transfer that recapitulates the ATS1 phenotype. We used a  
149 multidisciplinary approach that included patch-clamping, electrophysiological stimulation, as  
150 well as molecular biology, molecular dynamic (MD) modelling, and bioluminescence  
151 resonance energy transfer (BRET) to demonstrate that a disulfide bond break in the Kir2.1  
152 extracellular domain disrupts PIP<sub>2</sub>-dependent regulation, leading to channel dysfunction and  
153 triggering life-threatening arrhythmias.

154 **Materials & Methods**

155 ***See Supplemental Methods for more detail***

156

157 **Ethics Statement.** All animal experiment procedures conformed to EU Directive 2010/63EU  
158 and Recommendation 2007/526/EC. Skin biopsies were obtained from one patient carrying  
159 the Kir2.1 C122Y mutation after written informed consent, and consent to publish, in  
160 accordance with the Ethical Committee for Research of CNIC and the Carlos III Institute (CEI  
161 PI58\_2019-v3), Madrid, Spain. Animal protocols were approved by the local ethics  
162 committees and the Animal Protection Area of the Comunidad Autónoma de Madrid (PROEX  
163 111.4/20).

164

165 **Mice.** C57BL/6J mice, 4-5-weeks-old, were obtained from the Charles River Laboratories,  
166 and reared and housed in accordance with CNIC animal facility guidelines and regulations.

167

168 **Adeno-associated virus vector production, purification and mouse model generation.**

169 AAV vectors were generated using the cardiomyocyte-specific cardiac TroponinT proximal  
170 promoter (cTnT) and encoding wildtype Kir2.1 (Kir2.1<sup>WT</sup>) or the ATS1 Kir2.1 mutant  
171 (Kir2.1<sup>C122Y</sup>), followed by tdTomato report. Vectors were packaged into AAV serotype 9  
172 (AVV9) and produced by the triple transfection method, using HEK293T cells as described  
173 previously<sup>20,21</sup>. Mice were anesthetized with ketamine (60 mg/kg) and xylazine (20 mg/kg)  
174 via the intraperitoneal (i.p.) route. Thereafter,  $3.5 \times 10^{10}$  virus particles were inoculated  
175 intravenously (i.v.) through the femoral vein in a final volume of 50 $\mu$ L. Only well-inoculated  
176 animals were included in the studies. All experiments were performed 8-to-10 weeks after  
177 infection. *Ex-vivo* fluorescent signal confirming cardiac expression and distribution of protein  
178 expression was assessed as described.<sup>22</sup>

179

180 **Echocardiography.** Transthoracic echocardiography was performed blindly by an expert  
181 operator using a high-frequency ultrasound system (Vevo 2100, VisualSonics Inc., Canada)  
182 with a 40-MHz linear probe, and analyzed as described (in *Supplemental Methods*).

183

184 **Surface ECG recording.** Mice were anesthetized using isoflurane inhalation (0.8-1.0%  
185 volume in oxygen). Four-lead surface ECGs were recorded for 5 minutes using  
186 subcutaneous limb electrodes connected to an MP36R amplifier unit (BIOPAC Systems).  
187 Data acquisition and analysis were performed using AcqKnowledge software.

188

189 **In-vivo intracardiac recording and stimulation.** An octopolar catheter (Science) was  
190 inserted through the jugular vein and advanced into the right atrium (RA) and ventricle (RV)  
191 as previously described.<sup>23</sup> Atrial and ventricular arrhythmia inducibility was assessed by  
192 applying consecutive trains at 10Hz and 25Hz, respectively.

193

194 **Cardiomyocyte isolation.** The procedure was performed as described by Macías et al.<sup>24</sup>  
195 (See *Supplemental Methods*).

196

197 **Membrane fractionation, immunoprecipitation and immunoblotting.** Total protein was  
198 obtained from isolated Kir2.1<sup>WT</sup> and Kir2.1<sup>C122Y</sup> cardiomyocytes using RIPA buffer (150 mM  
199 NaCl, 10 mM Tris-HCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS and 0.1% Sodium  
200 deoxycholate) supplemented with protease inhibitor cocktail (Roche) and quantified by BCA  
201 protein assay (Bio-Rad). A total amount of 50 µg of protein was resolved in each lane on  
202 10% SDS-PAGE gels, electrotransferred onto 0.2 µm PVDF membrane (BioRad) and probed  
203 with specific antibodies. For membrane fractionation, cells were extracted and homogenized  
204 in ice-cold homogenization medium. After lysis, protein extract was processed according to  
205 manufacturer's specifications (Abcam). See further details in the *Supplemental Methods*,

206

207 **Bioluminescence Resonance Energy Transfer (BRET) Lipid binding assay.** HEK293T  
208 cells were transfected with 2 µg of plasmid encoding Kir2.1<sup>WT</sup> or Kir2.1<sup>C122Y</sup> protein fused  
209 with Nluc (nanoluciferase) in the C-terminal region. After 48h, the BRET assay was done in  
210 a 96-well plate as previously described.<sup>25</sup> See *Supplemental Methods* for details.

211

212 **Patch-clamping in isolated cardiomyocytes.** The whole-cell patch-clamp technique and  
213 data analysis procedures and internal and external solutions (**Supplementary Table 1**) were  
214 similar to those previously described.<sup>9-13</sup> Details are presented in the *Supplemental Methods*.

215

216 **Calcium dynamics assays.** Cytosolic Ca<sup>2+</sup> was monitored according to previously  
217 described protocols.<sup>26-28</sup> Briefly, cells were loaded with Fluo-4-AM (Invitrogen). Fluorescence  
218 was detected in line scan mode (usually 2 ms/scan), with the line drawn approximately  
219 through the center of the cell and parallel to its long axis.

220

221 **Dynamic modeling to predict Kir2.1-PIP<sub>2</sub> interaction.** For each monomer we used the  
222 pre-opened state of Kir2.2 bound to PiP<sub>2</sub> as a template (PDB code 3SPH) to conduct  
223 molecular dynamics (MD) modelling. We generated homology PiP<sub>2</sub> models binding to  
224 Kir2.1<sup>WT</sup>, Kir2.1<sup>C122Y</sup> homotetramer and Kir2.1<sup>WT/C122Y</sup> heterotetramer to study Kir2.1-PiP<sub>2</sub>  
225 interactions using 2000 ns MD. The CHARMM-GUI server allowed us to simulate both  
226 membrane and environment. - Please see *Supplemental Methods* for detailed description of  
227 the procedures.

228

229 **Statistical analyses.** We used GraphPad Prism software version 7.0 and 8.0. In general,  
230 comparisons were made using Student's t-test. Unless otherwise stated, we used one- or  
231 two-way ANOVA for comparison among more than two groups and Tukey correction for  
232 multiple comparisons. Data are expressed as mean ± SEM, and differences are considered  
233 significant at p<0.05.



## 234 **Results**

### 235 **Life-threatening arrhythmias in an ATS1 family with the Kir2.1<sup>C122Y</sup> mutation**

236 We screened a family with members suffering numerous idiopathic sudden loss-of-  
237 consciousness episodes using a targeted sequencing gene panel involved in arrhythmias  
238 (*RYR2*, *CASQ2*, *TRDN*, *CALM1* and *KCNJ2*). We identified a novel *de novo* potential  
239 pathogenic heterozygous missense variant c.365 A>T; p.Cys122Trp of the *KCNJ2* gene for  
240 ATS1 (LQTS type 7) in two family members (**Figure 1A-B**). The proband (patient II.2) was a  
241 16-year-old female of Caucasian origin who experienced several sudden loss of  
242 consciousness events of unknown origin. Initially, patient II.2 was diagnosed with mitral valve  
243 prolapse of the anterior leaflet without hemodynamic repercussions. The electrophysiological  
244 study was negative following a hospital admission for syncope and subsequent evidence of  
245 polymorphic ventricular extrasystoles refractory to antiarrhythmic drugs (propafenone,  
246 mexiletine and lidocaine). She continued with propranolol treatment (120 mg/d) combined  
247 with oral mexiletine (200mg/8h). At age 23, a single-chamber cardioverter-defibrillator (ICD)  
248 was implanted after several episodes of syncopal polymorphic ventricular tachycardia (PVT)  
249 and registering three appropriate discharges throughout ages 25-35 during sodium channel  
250 blocker administration (**Figure 1C**). ECG analysis revealed a corrected QT (QTc) interval in  
251 the upper limit of the normal range (470 ms) with pronounced U waves and polymorphic  
252 extrasystoles with frequent trigeminy episodes (**Figure 1D**). She is now 45 and currently  
253 under treatment with nadolol 120 mg/d and spironolactone 25 mg/d. The proband's son  
254 (patient III.1) remains asymptomatic at the age of 8. However, ECG analysis revealed a  
255 prolonged QTc interval of 490 ms with a widened T wave and prominent U waves (**Figure**  
256 **1E**), consistent with ATS1 symptoms.

257

### 258 **Cardiac conduction defects and arrhythmias in Kir2.1<sup>C122Y</sup> mice**

259 We used intravenous AAV-mediated cardiac specific gene transfer<sup>22</sup> to generate mice  
260 expressing Kir2.1<sup>WT</sup> or Kir2.1<sup>C122Y</sup>. We confirmed AAV infection throughout the heart and that  
261 cardiomyocytes stably expressed the specific targeted transgenes (**Supplemental Figure**  
262 **1**), with no cardiac morphological changes or contractile dysfunction evaluated by

263 echocardiography (**Supplemental Figure 1C and Sup. Figure 2**). On surface ECG,  
264 Kir2.1<sup>C122Y</sup> mice showed conduction alterations characteristic of the disease (**Figure 2A**).  
265 More importantly, Kir2.1<sup>C122Y</sup> mice had frequent premature ventricular complexes (PVCs)  
266 and runs of non-sustained PVT (**Figure 2B**) in agreement with the ATS1 patient's phenotype.  
267 Under stress conditions induced by isoproterenol (ISO, 5mg/Kg), Kir2.1<sup>C122Y</sup> mice developed  
268 PR and QRS prolongation. Compared with control, Kir2.1<sup>C122Y</sup> animals exhibited  
269 repolarization abnormalities with prolongation of the QT interval and occasional overlap of  
270 the T wave with the P wave of the following complex (**Figure 2C-D**). Intracardiac stimulation  
271 of the right atrium or ventricle used consecutive trains of stimuli at 10 and 25 Hz. Under basal  
272 conditions, Kir2.1<sup>C122Y</sup> mice had a significantly increased arrhythmia susceptibility with  
273 respect to Kir2.1<sup>WT</sup> (**Figure 2E-F**); upon stimulation, 5 out of 9 Kir2.1<sup>C122Y</sup> mice (55,5%)  
274 developed atrial or ventricular arrhythmias, including PVT, compared to 0 out of 7 Kir2.1<sup>WT</sup>  
275 mice (0%). ISO administration increased arrhythmia susceptibility in both atria and ventricles  
276 of Kir2.1<sup>C122Y</sup> (8 out of 9 mice, 88,9%), vs. Kir2.1<sup>WT</sup> (1 out of 7 mice, 14,2%). Altogether,  
277 these results indicate that the Kir2.1<sup>C122Y</sup> mutation recapitulates the ATS1 patient's cardiac  
278 electrical phenotype, establishing an arrhythmogenic substrate.

279

### 280 **Kir2.1<sup>C122Y</sup> subunits are able to form heterotetramers**

281 Kir2.1 channels can exist either as homo- or hetero-tetrameric complexes consisting  
282 of either four identical Kir2.1 subunits or in various combinations with the structurally related  
283 members of the Kir2.x subfamily of inward rectifier K<sup>+</sup> channels<sup>29</sup>. To clarify the mechanisms  
284 by which the C122Y mutation causes channel dysfunction in ATS1, we determined whether  
285 Kir2.1<sup>C122Y</sup> can assemble with WT subunits and traffic to the surface membrane  
286 (**Supplemental Figure 3**). Immunoprecipitation studies using differently tagged Kir2.1  
287 subunits were used to test whether the mutation affected subunit assembly. The HA and Myc  
288 epitope tags were incorporated into an external site that does not perturb channel activity<sup>30,31</sup>  
289 (**Supplemental Figure 3A**). In these studies, HEK293T cells were either co-transfected with  
290 Myc-tagged Kir2.1 (WT) or HA-tagged Kir2.1 (WT or C122Y) at a 1:1 ratio. Recovered  
291 immunoprecipitants on anti HA-bound beads were resolved by SDS-PAGE, and the extent

292 of HA-tagged channel subunit interaction was assessed using anti-Myc antibodies in  
293 immunoblots. As shown by the representative experiment (**Supplemental Figure 3B**), the  
294 wild-type Myc-Kir2.1 co-immunoprecipitated with both HA-tagged subunits, indicating the  
295 mutation does not alter subunit interaction. In addition, immunocytochemical analysis of co-  
296 transfected cells revealed that the Myc-tagged Kir2.1<sup>WT</sup> and HA-tagged Kir2.1<sup>C122Y</sup> subunits  
297 are highly co-localized (**Supplemental Figure 3C**), offering further evidence that the C122Y  
298 subunits are capable of assembling with the WT subunits in cells.

299

### 300 **Kir2.1<sup>C122Y</sup> subunits traffic to the cardiomyocyte surface membrane**

301 Kir2.1 localizes at two separate well-defined striated microdomains running parallel to  
302 each other at ~0.9  $\mu\text{m}$  intervals throughout the cardiomyocyte.<sup>24</sup> One microdomain  
303 corresponds with the t-tubules where Kir2.1 co-localizes with the voltage gated cardiac  
304 sodium channel Na<sub>v</sub>1.5 (~1.8  $\mu\text{m}$  spacing). The other is at the sarcoplasmic reticulum (SR)  
305 where Kir2.1 functions to control calcium homeostasis (**Figure 3A and B**).<sup>24</sup> Disruption of  
306 one or both microdomains leads to malfunction of Kir2.1 and Na<sub>v</sub>1.5 channels that might  
307 trigger arrhythmias. However, unlike the defective distribution pattern that was demonstrated  
308 for the trafficking deficient mutation Kir2.1 <sup>$\Delta$ 314-315</sup>,<sup>24</sup> immunolocalization and confocal image  
309 analysis of isolated ventricular cardiomyocytes from Kir2.1<sup>C122Y</sup> animals revealed an  
310 unaltered distribution pattern for both Kir2.1 and Na<sub>v</sub>1.5 channels (**Figure 3A and B**). When  
311 we determined the percentage of membrane expression using an anti-Na<sup>+</sup>/K<sup>+</sup> ATPase  
312 immunostaining, the results again showed a similar distribution of Kir2.1 and Na<sub>v</sub>1.5  
313 channels in Kir2.1<sup>WT</sup> and Kir2.1<sup>C122Y</sup> cells, with a small but significant reduction in Na<sub>v</sub>1.5  
314 accumulation level in mutant cardiomyocytes (**Figure 3C**). Similarly, on western blot, Na<sub>v</sub>1.5  
315 protein expression was lower for the mutant cardiomyocytes with a trend toward a decrease  
316 in total protein (**Figure 3D-E**). Trafficking of both Kir2.1 and Na<sub>v</sub>1.5 to their membrane  
317 microdomains depends in part on their classical route that involves incorporation into clathrin-  
318 coated vesicles at the trans-Golgi network marked by interaction with the adaptor protein  
319 complex-1 Y-adaptin subunit (AP-1).<sup>32</sup> Trafficking may also occur via an unconventional  
320 route directly from SR in a GRASP dependent manner.<sup>33</sup> To test whether Kir2.1<sup>C122Y</sup> disrupts

321 Kir2.1 trafficking we analyzed AP-1 and GRASP65 proteins by immunofluorescence of both  
322 WT and mutant cardiomyocytes. As shown in **Figure 3F-G**, the AP-1 expression profile was  
323 identical in both groups. Similarly, GRASP65 staining presented an F-function distribution  
324 (distance from particles to nearest neighbor particle) with no differences in either WT or  
325 mutant groups. Also, co-localization of Kir2.1 with GRASP65 was similar in both groups.  
326 From the foregoing the Kir2.1<sup>C122Y</sup> variant is able to form heterotetramers with WT subunits  
327 and retains trafficking ability. Taken together, these observations strongly suggest that the  
328 C122Y mutation leads to cardiac electrical alterations via mechanisms other than those  
329 recently demonstrated for the trafficking deficient  $\Delta$ 314-315 mutation.<sup>36</sup> This led us to further  
330 explore the biophysical and electrophysiological properties of the Kir2.1<sup>C122Y</sup> channel and  
331 determine whether the mutation directly alters potassium conductance and/or disrupts  
332 protein stability.

333

### 334 **Kir2.1<sup>C122Y</sup> cardiomyocytes exhibit defects in excitability and action potential duration**

335 We performed patch-clamping experiments in isolated cardiomyocytes from Kir2.1<sup>WT</sup>  
336 and Kir2.1<sup>C122Y</sup> expressing hearts. We focused on both  $I_{K1}$  and the sodium inward current  
337 ( $I_{Na}$ ) to test whether the impulse conduction disturbances and arrhythmias observed in this  
338 model of ATS1 are due to defects in one or both currents. The results show a 90% reduction  
339 in the outward  $I_{K1}$  density of Kir2.1<sup>C122Y</sup> compared with Kir2.1<sup>WT</sup> cardiomyocytes (**Figure 4A**),  
340 which explains why we were unable to obtain reliable current clamp measurements of AP  
341 characteristics, since the vast majority of Kir2.1<sup>C122Y</sup> cardiomyocytes (11 out of 12 or 91.7%)  
342 tested were substantially depolarized at rest (~-35mV) and unable to generate APs upon  
343 stimulation. Furthermore, surprisingly, Kir2.1<sup>C122Y</sup> cardiomyocytes showed a slight but  
344 significant decrease in  $I_{Na}$  density compared with controls (**Figure 4B**) with no significant  
345 changes in the voltage-dependence of current activation or inactivation (**Supplemental**  
346 **Figure 4**). These data further demonstrate that, while the mutant Kir2.1 protein traffics and  
347 is expressed at the membrane, it is dysfunctional and also reduces  $Na_v1.5$  function.  
348 Altogether, these results reinforce the hypothesis that conduction disturbances and  
349 arrhythmias in ATS1 patients are due to a defect in cardiomyocyte excitability.

350 As illustrated in **Figure 4C**, AP recordings revealed that, the 7 out of 12 (58,3%)  
351 Kir2.1<sup>C122Y</sup> cardiomyocytes that remained excitable after isolation generated significantly  
352 prolonged APs, early afterdepolarizations (EADs), triggered discharges and bi-stability of the  
353 RMP (**Figure 4D**). Accordingly, we analyzed the intracellular calcium dynamics in both WT  
354 and ATS1 mice. Confocal images of Ca<sup>2+</sup> dynamics showed that Kir2.1<sup>C122Y</sup> cardiomyocytes  
355 had an excitation-contraction (e-c) coupling defect with multiple abnormal spontaneous  
356 calcium release events during systole and diastole (**Figure 4E**). Since Ca<sup>2+</sup> movements  
357 across the sarcoplasmic reticulum (SR) are controlled by the ryanodine receptor (RyR<sub>2</sub>)-  
358 mediated Ca<sup>2+</sup> release and the Ca<sup>2+</sup>-ATPase (SERCA)-mediated Ca<sup>2+</sup> reuptake to-and-from  
359 the cytosol and SR lumen, we wondered whether protein alteration could happen in the  
360 Kir2.1<sup>C122Y</sup> mouse model. However, confocal images of protein localization profiles were  
361 identical in Kir2.1<sup>C122Y</sup> and Kir2.1<sup>WT</sup> cardiomyocytes, and total protein levels were also similar  
362 (**Figure 4F**). Since, K<sup>+</sup> flux across Kir2.1 SR channels contributes countercurrent to Ca<sup>2+</sup>  
363 movement,<sup>24</sup> we analyzed the intracellular Ca<sup>2+</sup> dynamics in both controls and ATS1 mice  
364 (**Figure 4G-H**). Cardiomyocytes expressing Kir2.1<sup>WT</sup> and Kir2.1<sup>C122Y</sup> showed similar Ca<sup>2+</sup>  
365 transient decay under acute caffeine administration in intact cardiomyocytes (**Figure 4G-H**).  
366 These results indicate that the Ca<sup>2+</sup> alterations are due to functional defects at the  
367 sarcolemma, including RMP depolarization and reduced excitability, rather than Kir2.1  
368 dysfunction at the SR.

369

### 370 **Disulfide bond loss reorganizes tridimensional channel structure interfering with** 371 **Kir2.1<sup>C122Y</sup>-PIP<sub>2</sub> binding**

372 Cys<sub>122</sub> localizes at the extracellular loop of the Kir2.1 channel, immediately after the  
373 first transmembrane domain, where it is cross-linked by an intramolecular disulfide bond with  
374 Cys<sub>154</sub> at the beginning of the second transmembrane  $\alpha$ -helix (**Figure 5A**). Both residues  
375 and their disulfide bond are conserved across the Kir family (**Figure 5B**), which is crucial for  
376 proper channel folding, as they may help accommodate the extracellular loop in an optimal  
377 tridimensional structure.<sup>18</sup> We used *in-silico* homology modelling to derive predictions of the  
378 molecular structure of the Kir2.1<sup>C122Y</sup> mutant channel, and thus understand the possible

379 mechanisms underlying its dysfunction. Atomic level modelling showed that, compared to  
380 the WT channel, Kir2.1<sup>C122Y</sup> undergoes a clear reorganization (TMscore 0.73; RDMS: ~6Å  
381 for homotetramer or TMscore 0.78; RDMS: ~7Å for heterotetramer) (**Figure 5C-D**). The  
382 Gibbs free-energy values for Kir2.1<sup>C122Y</sup> were more positive compared to WT (WT: 4801.404  
383 vs C122Y: -4131.754 for homo or -2274.207 for heterotetramer) (**Figure 5D**). This indicates  
384 a more unstable state in Kir2.1<sup>C122Y</sup> homo- and heterotetrameric channels, suggesting that  
385 the incorporation of mutant subunit could affect the integrity of the WT monomers or even  
386 affect the macromolecular channelosome complex, including Kir2.1 and Na<sub>v</sub>1.5.

387 To predict Kir2.1-PIP<sub>2</sub> interaction ability we incorporated PIP<sub>2</sub> molecules in the  
388 simulation. Our results showed an altered Kir2.1<sup>C122Y</sup>-PIP<sub>2</sub> interaction following a dominant-  
389 negative pattern. The Kir2.1<sup>WT/C122Y</sup> heterotetramer presented 2 out of 4 PIP<sub>2</sub> molecules  
390 compared with the complete set of 4 PIP<sub>2</sub> in the Kir2.1<sup>WT</sup> homotetramer, one per monomer  
391 (**Figure 5E**). Notably, the Kir2.1<sup>C122Y</sup> homotetramer abolished completely PIP<sub>2</sub> interaction, in  
392 accordance with the I<sub>K1</sub> current suppression in homozygous mutant conditions in C154F<sup>34</sup>  
393 and C122Y-expressing HEK cells (**Supplemental Figure 5**). Taken together, these *in-silico*  
394 homology experiments predict that the loss of the highly-conserved extracellular Cys122-to-  
395 Cys154 disulfide bond in channels containing the Kir2.1<sup>C122Y</sup> isoform may result in a clear  
396 atomic re-structuration with loss of function by mechanisms that include, at least in part, a  
397 pronounced interference with the PIP<sub>2</sub> binding pocket.

398

### 399 **Cys122- Cys154 disulfide bond breakup disrupts Kir2.1-PiP<sub>2</sub> interaction dynamics.**

400 We conducted *in-silico* molecular dynamics (MD) studies to more rigorously establish  
401 whether the extracellular Cys122-to-Cys154 disulfide bond breakup in the Kir2.1<sup>C122Y</sup> mutant  
402 channel disrupts Kir2.1-PIP<sub>2</sub> interaction (**Figure 6**). We generated Kir2.1 homology models  
403 bound to a single PIP<sub>2</sub> molecule per monomer in Kir2.1<sup>WT</sup>, Kir2.1<sup>C122Y</sup> homotetramer and  
404 Kir2.1<sup>WT/C122Y</sup> heterotetramer to study Kir2.1-PIP<sub>2</sub> interactions throughout an individual 2000  
405 ns MD replica (see *Supplemental Methods* for details of the overall approach). For each  
406 monomer we used the pre-opened state of Kir2.2 bound to PIP<sub>2</sub> as a template (PDB code  
407 3SPH).<sup>35</sup> The CHARMM-GUI server allowed us to simulate both membrane and environment

408 **(Figure 6A-B)**; we then performed three independent replicas for each model. First, we  
409 evaluated the conformational changes in the extracellular space by monitoring either C<sub>122</sub> or  
410 Y<sub>122</sub> backbone dihedral angles along the 2000 ns MD. Comparative analysis showed only  
411 28% conserved-frames in backbone dihedral angles, while 72% presented a shift in  $\Phi$ -  
412 dihedral angle from around -70° to -140° shortly after the first 100 ns **(Figure 6C and**  
413 **Supplemental Figure 6)**. The Y<sub>122</sub> sidechain reorientation resulted in movement of D<sub>112</sub>, and  
414 consequent break of the internal hydrogen-bonding network between D<sub>112</sub> and the H<sub>110</sub>  
415 sidechain and the NH backbone of C<sub>122</sub> within the extracellular loop **(Supplemental Figure**  
416 **7)**. Thus, hydrogen bonds between the H<sub>110</sub> sidechain and the Y<sub>122</sub> backbone were either  
417 absent or generally present in less than 50% of the frames. In addition, in several of the MD  
418 simulations a new hydrogen bond was formed between D<sub>112</sub> and K<sub>117</sub>. Therefore, C122Y  
419 leads to a reorganization of the hydrogen-bonding network of the extracellular loop that might  
420 alter Kir2.1 function. **(Supplemental Table 2)**. Nevertheless, neither of the two Y<sub>122</sub>  
421 conformations observed in the MD led to a significant change in the relative disposition of  
422 the outer and inner helices, as shown by the measurement of the distance between two  
423 opposite residues (I<sub>106</sub> and I<sub>156</sub>) located near the extracellular side of each of those helices  
424 **(Supplemental Figure 8)**.

425 Kir2.1-PIP<sub>2</sub> interactions involve hydrophobic contacts with PIP<sub>2</sub> acyl chains, and more  
426 specific polar interactions between PIP<sub>2</sub> phosphates and positively charged Kir2.1 residues  
427 at the transmembrane domain (TMD)-to-cytoplasmic domain (CTD) interface.<sup>35,36</sup> A detailed  
428 study of the atomic Kir2.1-PIP<sub>2</sub> hydrogen-bonding distance yielded a global loss of hydrogen  
429 bonds in the Kir2.1<sup>C122Y</sup> channels that directly affected PIP<sub>2</sub> interactions. Comprehensive  
430 analysis of the R<sub>80</sub>W<sub>81</sub>R<sub>82</sub> motif and the lysine-cluster K<sub>182</sub>K<sub>185</sub>K<sub>187</sub>K<sub>188</sub> of the helicoidal CTD-  
431 to-TMD linker (C-linker) **(Figure 6D)** showed a clear reduction in hydrogen bonding capacity  
432 in both hetero- and homotetrameric Kir2.1<sup>C122Y</sup> channels throughout the 2000 ns MD **(Figure**  
433 **6F and Supplementary Table 3)**. Our simulations predict that, compared with the Kir2.1<sup>WT</sup>  
434 tetramers, Kir2.1<sup>WT/C122Y</sup> and Kir2.1<sup>C122Y</sup> channels progressively lose the characteristic  
435 hydrogen bond of the PIP<sub>2</sub> 1' phosphate with R<sub>80</sub>W<sub>81</sub>R<sub>82</sub>, particularly R<sub>82</sub>, and the PIP<sub>2</sub> 4' and  
436 5' phosphates with the C-linker **(Supplemental Table 3)**. As expected, the unmutated chains

437 (chains A and C) in Kir2.1<sup>WT/C122Y</sup> heterotetramers showed a similar behavior to WT chains  
438 **(Supplemental Table 3)**.

439 Upon PIP<sub>2</sub> binding at the interface between TMD and CTD, the C-linker undergoes a  
440 disorder-to-order transition bringing both domains closer together. Thus, the G-loop wedges  
441 into the TMD causing the inner helix gate to open.<sup>35</sup> Follow-up of this transition showed that  
442 the C-linker loses the hydrogen bonds characteristic of  $\alpha$ -helix structures in the Kir2.1<sup>C122Y</sup>  
443 hetero- and homotetramer. In comparison, Kir2.1<sup>WT</sup> maintained a more pronounced  
444 hydrogen-bond network between K<sub>188</sub>-E<sub>191</sub> and R<sub>189</sub>-T<sub>192</sub>, as well as the K<sub>185</sub>, P<sub>186</sub>, K<sub>187</sub> and  
445 N<sub>190</sub> residues, indicating that in the mutant channels the N- and C-terminal of the C-linker  
446 helix were destructured faster than WT **(Figure 6E and Supplemental Table 4)**.  
447 Interestingly, at the beginning of the C-linker motif, the dihedral angles of P<sub>186</sub> were within  
448 those of  $3_{10}$  helix  $\phi$  (-71) and  $\psi$  (-18) in the PIP<sub>2</sub>-bound Kir2.1<sup>WT</sup> structures. However, in the  
449 Kir2.1<sup>C122Y</sup> hetero- and homotetramer the  $\phi$  dihedral varied in correlation with a progressive  
450 loss of the C-linker's helical character **(Figure 6G)**. Compared with Kir2.1<sup>WT</sup>, the Kir2.1<sup>C122Y</sup>  
451 homotetramer had a lower percentage of frames corresponding to the dihedral  $3_{10}$  helix in  
452 P<sub>186</sub> (Kir2.1<sup>C122Y</sup>: 17% at 1000 ns, 8% at 2000 ns; Kir2.1<sup>WT</sup>: 33% at 1000 ns, 17% at 2000  
453 ns), the percentages of the heterotetramer being intermediate **(Figure 6G)**.

454 Finally, we measured the distance between C $\alpha$  carbons of representative pore  
455 constriction Ile<sub>176</sub> and Met<sub>180</sub> residues at the TM and A<sub>306</sub> of the G-loop from opposite chains  
456 to study the pore opening state during the 2000 ns MD **(Figure 6H and Supplemental**  
457 **Figure 8)**<sup>36,37</sup>. For both Ile<sub>176</sub> and Met<sub>180</sub> the distance between the A-B and between the B-D  
458 chains decreased progressively in hetero and more pronouncedly in homo mutant channels,  
459 with larger values for WT chains in the first 500 ns, which likely correlated with a more open  
460 state in WT channels **(Figure 6I)**. Longer MD times using WT channels showed that the  
461 distance among the C $\alpha$  carbons of the above residues decreased in two opposite monomers  
462 and led to an increase in the distance between the other two monomers, as observed in the  
463 gating mechanism for KirBac3.1.<sup>38</sup> Similarly, the C $\alpha$ -carbon distance between A<sub>306</sub> residues  
464 in the G-loop decreased in the mutant hetero- and more pronouncedly in the homotetramer  
465 **(Supplemental Figure 9)**. These results strongly suggest that the extracellular disulfide



466 bond break of Kir2.1<sup>C122Y</sup> closes the channel by altering the Kir2.1-PIP<sub>2</sub> hydrogen-bond  
467 network, which in the WT stabilizes PIP<sub>2</sub> function to maintain the open state of the channel.

468

#### 469 **Kir2.1<sup>C122Y</sup> has a reduced sensitivity to, and binding capacity for PIP<sub>2</sub>**

470 To test for PIP<sub>2</sub> binding to Kir2.1, we fused a nanoluciferase (Nluc) to the C-terminus of the  
471 channel and used a soluble fluorescent PIP<sub>2</sub> (FL-PIP<sub>2</sub>) analog suitable for binding to Kir2.1.<sup>25</sup>

472 Activation of Nluc produced a FL-PIP<sub>2</sub>-dependent bioluminescence resonance energy  
473 transfer (BRET) signal specific for Kir2.1 as shown by the cartoon of the assay design in

474 **Figure 7A**. HEK293T cells were transfected with the WT and C122Y mutant version,

475 respectively, and a bioluminescence assay was performed. We included another Kir2.1

476 mutant version with a known mutation interfering with PIP<sub>2</sub>-Kir2.1 channel interaction as a

477 negative control (Kir2.1<sup>R218W</sup>). Our results showed that PIP<sub>2</sub> binds with high affinity to

478 Kir2.1<sup>WT</sup> but, as expected cannot directly bind to Kir2.1<sup>C122Y</sup>, such as we observed for

479 Kir2.1<sup>R218W</sup> (**Figure 7B**). To test the sensitivity of Kir2.1 to PIP<sub>2</sub>, we performed inside-out

480 patch-clamping of the Kir2.1<sup>WT</sup> and the heterozygous condition Kir2.1<sup>WT/C122Y</sup> currents in co-

481 transfected HEK293T cells at a 1:1 ratio. We recorded I<sub>K1</sub> in both basal condition and under

482 increasing concentrations of PIP<sub>2</sub> (25 and 50 µg/ml PIP<sub>2</sub>). The results showed that while in

483 Kir2.1<sup>WT</sup>, PIP<sub>2</sub> increased the inward K<sup>+</sup> current in a dose-dependent manner, the

484 Kir2.1<sup>WT/C122Y</sup> mutation blunted the sensitivity to PIP<sub>2</sub> (**Figure 7C-D**). Both groups showed an

485 unaltered outward current. Taken together, these results confirm the inability of Kir2.1<sup>C122Y</sup>

486 channels to functionally interact with PIP<sub>2</sub> molecules that allow proper channel function,

487 according to the dominant negative effect expected from patient data.

488

#### 489 **Discussion**

490 We report on the first human ATS1 mutation, C122Y, that breaks the Cys122-to-

491 Cys154 disulfide bond in the extracellular domain of the tridimensional Kir2.1 structure.

492 The disruption leads to defects in PIP<sub>2</sub>-dependent regulation, exerting a dominant

493 negative effect with Kir2.1 tetramer channel dysfunction and life-threatening arrhythmias.

494 Our AAV-mediated mouse model recapitulates *in-vivo* the ECG phenotype of the ATS1

495 patient carrying the C122Y mutation. ISO administration led to progressive further  
496 prolongation in the PR, QRS, and QT intervals. In addition, the mutation increases  
497 susceptibility to pacing-induced arrhythmogenic events of high severity (>1 second) in  
498 Kir2.1<sup>C122Y</sup> animals relative to controls, including non-sustained ventricular tachycardias  
499 similar to those observed on the proband's ECG. Isolated cardiomyocytes from Kir2.1<sup>C122Y</sup>  
500 mice exhibited defects produced by decreased  $I_{K1}$  and  $I_{Na}$  compared to controls, including a  
501 significantly depolarized RMP and reduced excitability. They also displayed prolonged  
502 APD, and in many cases EADs, bi-stability of the RMP and spontaneous calcium release  
503 events. The bistable resting membrane potential shown by some of the Kir2.1<sup>C122Y</sup>  
504 cardiomyocytes may have been in part be due to the modification of the overall  $I_{K1}$  IV relation  
505 shape produced by the mutation. As demonstrated many years ago by Gadsby and  
506 Cranefield (1977) in Purkinje fibers, the existence of two possible stable resting potentials  
507 requires that the net steady-state IV relationship be "N-shaped," with two zero-current  
508 intercepts in regions of positive slope conductance.<sup>39</sup> A third unstable intercept occurs in a  
509 region of negative slope conductance. In the case of the Kir2.1<sup>C122Y</sup> cardiomyocyte, the  
510 reduced Kir2.1 outward current at voltages between -60 and 0 mV, counterbalanced by the  
511 inward background conductance carried predominantly by sodium and calcium ions,  
512 generated an N-shaped current-voltage relation that crossed the voltage axis three times  
513 allowing two levels of resting membrane potential. Altogether, our results provide a potential  
514 mechanism for the spontaneous and induced arrhythmias observed in our ATS1 mouse  
515 model. While at baseline  $Ca^{2+}$  dynamics were similar to control after caffeine administration,  
516 ISO increased arrhythmia inducibility, suggesting abnormal  $Ca^{2+}$  dynamics transients.<sup>24</sup>

517 Our *in-silico* homology modelling of the tridimensional Kir2.1 structure helps us  
518 understand the structural mechanisms underlying Kir2.1<sup>C122Y</sup> dysfunction. Loss of the  
519 extracellular disulfide bond clearly alters the tridimensional structure and disrupts channel  
520 activity despite apparently normal Kir2.1<sup>C122Y</sup> channel trafficking to the sarcolemma.  
521 However, despite channel reorganization, Kir2.1<sup>C122Y</sup> still maintains a 78-84% similarity with  
522 Kir2.1<sup>WT</sup> (TMscore: mutant heterotetramer: 0.7806 vs mutant homotetramer: 0.8391), which  
523 suggests a failure of Kir2.1<sup>C122Y</sup> interaction with one or more key regulatory elements required

524 for proper channel function. PIP<sub>2</sub> signaling is a top candidate. PIP<sub>2</sub> has emerged as a central  
525 subcellular mechanism for controlling ion channels and the excitability of nerves and cardiac  
526 muscle.<sup>40</sup> PIP<sub>2</sub> acts as a cofactor for proper Kir2.1 activity at the cell membrane. Kir2.1  
527 channel-PIP<sub>2</sub> interactions are crucial for channel activity and regulation, and defects in PIP<sub>2</sub>  
528 binding constitute a major mechanism of Kir2.1 dysfunction underlying the loss-of-function in  
529 several ATS1.<sup>9</sup>

530 Our MD simulations with a single PIP<sub>2</sub> molecule bound per monomer during 2000 ns  
531 MD replicas revealed that the mutation increased the probability of change in the Y<sub>122</sub> Φ-  
532 dihedral angle leading to an altered hydrogen bond network in the extracellular loop.  
533 However, regardless of whether or not the dihedral angle varied, the distance between inner  
534 and outer helices remained unchanged. Nonetheless, the mutation triggered structural  
535 changes, particularly at the C-linker, which directly modified the PIP<sub>2</sub> binding site comprising  
536 amino acids from two main structural regions of the channel. According to the Kir2.2 channel  
537 X-ray crystal structure (PDB code 3SPH), the 1' PIP<sub>2</sub> phosphate interacts with amino acids  
538 forming the sequence RWR (R<sub>80</sub>W<sub>81</sub>R<sub>82</sub>). This sequence is conserved (as RWR or KWR)  
539 among many different Kir channels and is located at the N-terminus of the outer helix.<sup>35</sup> The  
540 RWR motif forms a binding site in which the 1' phosphate caps the helix and is cradled by  
541 main-chain amide nitrogen atoms and the guanidinium groups of the two arginine residues.  
542 The tryptophan (W<sub>80</sub>) residue appears to anchor to the end of the outer helix at the membrane  
543 interface and also interact with one of the acyl chains. Similarly, 4' and 5' PiP<sub>2</sub> phosphates  
544 interact and form hydrogen bonds with the helicoidal internal sliding helix (C-linker) at the  
545 end of the TM2 K<sub>183</sub>, K<sub>186</sub>, K<sub>188</sub> and K<sub>189</sub> residues in Kir2.2.<sup>35</sup> Throughout the 2000 ns MD,  
546 hydrogen bonds between Kir2.1 and PIP<sub>2</sub> decreased more rapidly for mutant channels  
547 compared to Kir2.1<sup>WT</sup>. Specifically, the PIP<sub>2</sub> 1' phosphate cap lost its interaction with the  
548 R<sub>80</sub>W<sub>81</sub>R<sub>82</sub> triad, particularly R<sub>82</sub>, which appears strongly bound to WT monomers for longer  
549 simulation time (**Supplemental Table 2**).

550 PIP<sub>2</sub> binding is known to induce a large conformational change in Kir channels  
551 leading to the formation of two new helices, an N-terminal extension of the 'interfacial' helix  
552 and a 'tether' helix at the C-linker.<sup>35,36</sup> The flexible expansion of the C-linker contracts to a

553 compact helical structure involving translation of the CTD  $\sim 6\text{\AA}$  towards the TMD, where it  
554 remains anchored and allows opening of the inner gate of the helix.<sup>35,36,45-47</sup> Importantly,  
555 separation between helices comes about as a result of slight splaying, but more significantly  
556 rotation of the inner helices, which moves hydrophobic amino acid side chains away from the  
557 ion pathway.<sup>35</sup> Our MD simulation showed the C-linker disorganizing faster in Kir2.1<sup>C122Y</sup>  
558 homo- and heterotetramer during the 2000 ns MD compared to WT channels, according to  
559 the loss of dihedral angles of P<sub>186</sub> within those of the 3<sub>10</sub>-helix structure. These results  
560 highlight a rapid release of PIP<sub>2</sub> molecules leading to channel closure, in accordance with  
561 the decreases in the C $\alpha$ -C $\alpha$  distance observed in the pore constriction residues Ile<sub>176</sub>, Met<sub>180</sub>  
562 and A<sub>306</sub>, which also appeared barely dynamic over 2000 ns MD. In agreement, other studies  
563 have shown that P<sub>186</sub> mutations lead to channel assembly, but with significantly reduced PIP<sub>2</sub>-  
564 binding capacity.<sup>41</sup> Taken together, these results suggest that C122Y induces a  
565 reorganization of the chains starting extracellularly and is transmitting along the channel to  
566 finally interrupts PIP<sub>2</sub>'s function. Nonetheless, the precise mechanism by which the C122Y  
567 mutation interferes with Kir2.1 binding to PIP<sub>2</sub> molecules is beyond the scope of this study  
568 and remains to be fully elucidated.

569 Taking advantage of the BRET lipid binding assay, our results clearly show a  
570 significant decrease in the percentage of BRET signal in Kir2.1<sup>C122Y</sup> channels, similar to the  
571 reduction in BRET signal for Kir2.1<sup>R218W</sup> channels, with a well-known failure to interact with  
572 PIP<sub>2</sub>.<sup>10</sup> We next directly measured the functional effects of PIP<sub>2</sub> on Kir2.1<sup>WT</sup> and  
573 heterozygous Kir2.1<sup>WT/C122Y</sup> channels in inside-out voltage-clamped membrane patches from  
574 transfected HEK293T cells. Altogether, the results showed that the C122Y mutation  
575 attenuated the maintenance of the I<sub>k1</sub> current over time with increasing PIP<sub>2</sub> concentration,  
576 which explained the lack of PIP<sub>2</sub>-dependent I<sub>k1</sub> current. Thus, we validated the *in-silico* MD  
577 predictions and the demonstration by BRET that the Kir2.1<sup>C122Y</sup> mutation breaks the disulfide  
578 bonds in the Kir2.1 extracellular domain, altering PIP<sub>2</sub>-dependent regulation to finally lead to  
579 channel dysfunction.

580 Interestingly, Macías et al.<sup>24</sup> have recently shown an SR microdomain of functional  
581 Kir2.1 channels contributing to intracellular Ca<sup>2+</sup> homeostasis that could explain the

582 phenotypic overlapping between ATS1 and catecholaminergic polymorphic ventricular  
583 tachycardia (CPVT) in some patients.<sup>42,43</sup> Ca<sup>2+</sup> fluxes across the SR membrane are  
584 bidirectional, and need a charge-compensating countercurrent ensuring that the SR  
585 membrane potential remains near 0 mV during the e-c coupling process.<sup>44,45</sup> Importantly, our  
586 results demonstrate that intracellular Ca<sup>2+</sup> homeostasis was similar in WT and C122Y under  
587 acute caffeine administration in intact isolated cardiomyocytes, suggesting that the SR Kir2.1  
588 channel population is not regulated in a PIP<sub>2</sub>-dependent manner. However, a role for  
589 intracellular Ca<sup>2+</sup> in arrhythmogenesis provoked by Kir2.1<sup>C122Y</sup> was evidenced only after  
590 overloading the SR by ISO administration. The results suggest that while sarcolemmal  
591 Kir2.1<sup>C122Y</sup> channels fail to conduct potassium through PIP<sub>2</sub>-dependent mechanisms, SR  
592 Kir2.1<sup>C122Y</sup> channels remain functional independently of PIP<sub>2</sub> activity. In support of such an  
593 idea, Katan et al. demonstrated that PiP<sub>2</sub> is exclusively involved in sarcolemmal activities,  
594 including controlling Kir2.1 function.<sup>46</sup>

595 Kir2.1 channels are part of large multiprotein complexes comprising components of  
596 the cytoskeleton, regulatory kinases and phosphatases, trafficking proteins, extracellular  
597 matrix proteins, and even other ion channels.<sup>47-49</sup> This probably explains in part the wide  
598 variety of clinical phenotypes found in different families with the same mutation and even  
599 within the same family.<sup>3</sup> Kir2.1 forms channelosomes with Na<sub>v</sub>1.5, which indicates that the  
600 disease should no longer be considered in the simplistic terms of "monogenic" disorder.<sup>2</sup> In  
601 fact, as our results show, it would not be correct to assume that the arrhythmic phenotype  
602 manifested by the patient is directly due to the mutation in question, but we must also  
603 consider potential modifications on the channel's interacting proteins. Therefore, the  
604 paradigm-shifting premise of this work is that we can no longer consider inherited  
605 arrhythmogenic diseases in terms of dysregulation of a single protein, because alteration of  
606 any member of a particular multiprotein complex has the potential to modify the function of  
607 associated proteins, resulting in a more complex disease. In this sense, the phenotypic  
608 manifestations in ATS1 are only understood by considering the wide range of proteins with  
609 which the altered ion channels interact.<sup>49</sup> Our results show that Kir2.1<sup>C122Y</sup> not only reduces  
610 I<sub>K1</sub> but also I<sub>Na</sub> in isolated mouse cardiomyocytes carrying the mutation. However, the C122Y

611 mutation does not affect trafficking of ether Kir2.1 or Nav<sub>v</sub>1.5 to the sarcolemma, suggesting  
612 new regulatory pathways for channelosome function. To further analyze molecular  
613 mechanisms involving Nav<sub>v</sub>1.5 regulation, we studied channelosome homeostasis of both  
614 Kir2.1 and Nav<sub>v</sub>1.5 proteins due to the differences in Gibbs free-energy values (WT: 4801.404  
615 vs C122Y: -4131.754 for homo or -2274.207 for heterotetramer). Cardiomyocytes were  
616 treated with cycloheximide (CHX)<sup>50</sup>, a ribosomal RNA transcription inhibitor, for periods of 8,  
617 16 and 24 hours at final concentrations of 100 µg/ml (**Supplemental Figure 10**). Interruption  
618 of protein synthesis resulted in a decrease of total Kir2.1 protein after 24 hours treatment  
619 compared to control (**Supplemental Figure 10A**). Immunostaining showed a significant co-  
620 localization with Rab5, protein involved in early endosomal formation (**Supplemental Figure**  
621 **10B**), suggesting protein instability. Similarly, CHX decreased total Nav<sub>v</sub>1.5 protein after 8  
622 hours confirming the reduction in cell surface expression (**Supplemental Figure 10C**).  
623 However, regulation of Nav<sub>v</sub>1.5 in these patients remains unclear. Reductions in Nav<sub>v</sub>1.5  
624 function/expression provide a slow-conduction substrate for cardiac arrhythmias. Van  
625 Bemmelen et al. demonstrate that Nav<sub>v</sub>1.5 can be ubiquitinated in heart tissues and that the  
626 ubiquitin-protein ligase Nedd4-2 acts on Nav<sub>v</sub>1.5 by decreasing the channel density at the cell  
627 surface<sup>51</sup>. Furthermore, in conditions like heart failure, elevated [Ca<sup>2+</sup>]<sub>i</sub> increased Nedd4-2,  
628 interaction between Nedd4-2 and Nav<sub>v</sub>1.5, and Nav<sub>v</sub>1.5 ubiquitination with consequent  
629 degradation<sup>52</sup>, suggesting a crucial role of Nedd4-2 in Nav<sub>v</sub>1.5 downregulation in heart  
630 disease. We looked for the expression in Nedd4-2 and our results showed a similar total  
631 expression of Nedd4-2 in both Kir2.1<sup>WT</sup> and Kir2.1<sup>C122Y</sup> cardiomyocytes, indicating that other  
632 regulatory pathways control the expression of Nav<sub>v</sub>1.5 at the cell surface membrane as a  
633 consequence of the Kir2.1<sup>C122Y</sup> mutation (**Supplemental Figure 10D**). Further studies are  
634 needed to elucidate the regulation of the Nav<sub>v</sub>1.5 channel associated with the Kir2.1<sup>C122Y</sup>  
635 mutation, but our data suggest a complex mechanism involved in channelosome function.

636 The potential clinical impact of this novel paradigm is groundbreaking: understanding  
637 the Kir2.1 modulation by its multiple interacting molecules will significantly improve our  
638 knowledge of channel function and of inherited and acquired arrhythmogenic cardiac  
639 diseases. It should also lay the groundwork for the generation of innovative, effective and

640 safe approaches to prevent SCD in these and other devastating cardiac disease. Compared  
641 Together with previous data,<sup>24</sup> all the results shown here support the hypothesis that the  
642 molecular mechanisms that increase the susceptibility to arrhythmias and SCD in ATS1 are  
643 different depending on the specific mutation, so that pharmacological treatment and clinical  
644 management should be different for each patient.

645 In conclusion, using AAV-mediated gene transfer we have generated a mouse model  
646 that recapitulated the electrocardiographic ATS1 phenotype of probands. ISO administration  
647 prolonged the PR, QRS and QT duration, and increased susceptibility to arrhythmogenic  
648 events of high severity. *In-silico* MD studies showed that the loss of the extracellular disulfide  
649 bond leads to channel closure by altering the Kir2.1- PIP<sub>2</sub> hydrogen-bonding network. BRET  
650 and inside-out patch-clamping experiments confirmed the low ability of the Kir2.1<sup>C122Y</sup> to  
651 properly bind PIP<sub>2</sub> in sarcolemma. Altogether, this is the first demonstration that the break  
652 disulfide bond in the extracellular domain of the Kir2.1 channel results in defects in PIP<sub>2</sub>-  
653 dependent regulation, leading to channel dysfunction and life-threatening arrhythmias.

654 **FUNDING:** Supported by National Institutes of Health R01 HL163943; La Caixa Banking  
655 Foundation under the project code LCF/PR/HR19/52160013; grant PI20 / 01220 of the public  
656 call “Proyectos de Investigación en Salud 2020” (PI-FIS-2020) funded by Instituto de Salud  
657 Carlos III (ISCIII); MCIU grant BFU2016-75144-R and PID2020-116935RB-I00, and co-  
658 funded by Fondo Europeo de Desarrollo Regional (FEDER); and Fundación La Marató de  
659 TV3 (736/C/2020); and CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid,  
660 Spain. We also receive support from the European Union's Horizon 2020 Research and  
661 Innovation programme under grant agreement GA-965286; to JJ; Grant PID2021-  
662 126423OB-C22 (to MMM) funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A  
663 way of making Europe”; Grant PID2019-104366RB-C22 (to MGR), funded by  
664 MCIN/AEI/10.13039/501100011033; Funding provided by the Dynamic Microscopy and  
665 Imaging Unit - ICTS-ReDib Grant ICTS-2018-04-CNIC-16 funded by MCIN/AEI  
666 /10.13039/501100011033 and ERDF; project EQC2018-005070-P funded by MCIN/AEI  
667 /10.13039/501100011033 and FEDER. CNIC is supported by the Instituto de Salud Carlos  
668 III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and  
669 is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by  
670 MICIN/AEI/10.13039/501100011033). AIM-M holds a FPU contract (FPU20/01569) from  
671 Ministerio de Universidades. LKG holds a FPI contract (PRE2018-083530), Ministerio de  
672 Economía y Competitividad de España co-funded by Fondo Social Europeo ‘El Fondo Social  
673 Europeo invierte en tu futuro’, attached to Project SEV-2015-0505-18-2. IMC holds a PFIS  
674 contract (FI21/00243) funded by Instituto de Salud Carlos III and Fondo Social Europeo Plus  
675 (FSE+), ‘co-funded by the European Union’. MLVP held contract PEJD-2019-PRE/BMD-  
676 15982 funded by Consejería de Educación e Investigación de la Comunidad de Madrid y  
677 Fondo Social Europeo ‘El FSE invierte en tu futuro’.

678

## 679 **DISCLOSURES**

680 None

681

## 682 **ACKNOWLEDGEMENTS**

683 We thank the CNIC Viral Vectors Unit for producing the AAV9. The confocal experiments  
684 were carried out in the CNIC Microscopy and Dynamic Imaging Unit. We thank the CNIC  
685 Bioinformatics Unit for generating the *in-silico* homology modelling simulations, F-function  
686 analysis and helping in their discussion. We also thank the Centro de Supercomputación de  
687 Galicia (CESGA) for use of the Finis Terrae III supercomputer to perform molecular dynamics  
688 studies.



689

690 **AUTHOR CONTRIBUTION**

691 F.M.C. and J.J. co-designed the experiments; F.M.C. performed most of the experiments;  
692 A.M. and A.I.M.M are author for cellular electrophysiology; A.D., E.Z., and J.J.J. provided  
693 clinical data; L.K.G. supported optical mapping experiments: L.K.G. and F.M. were in charge  
694 of *in-silico* homology modelling and molecular docking studies; A.D.A, M.M.M. and M.G.R.  
695 performed molecular dynamics simulation and analysis and provided funding; M.L.V., P.S.P.,  
696 J.R.R., S.A.S., I.M.C., F.B.J., A.B.B. and J.A.B. provided technical support, discussions and  
697 revisions; F.M.C. and J.J. co-wrote the manuscript and conceived the study; J.J. provided  
698 supervision, funding and revisions; All authors discussed the results and commented on and  
699 approved the manuscript.

700

701 **CORRESPONDING AUTHORS**

702 Correspondence to José Jalife or Francisco M. Cruz.

703

704 **SUPPLEMENTAL INFORMATION**

705 Extended Materials and Methods

706 Supplementary Figures 1-10

707 Supplementary Tables 1-4

708 **Figure legends**

709 **Figure 1. Genetics and ECG phenotype of ATS1 family members with Kir2.1<sup>C122Y</sup>**  
710 **mutation. A:** DNA sequences derived from proband's genomic DNA. The trace shows a  
711 heterozygous substitution of guanine to adenine resulting in the C122Y amino acid change.  
712 **B:** Family pedigree according to the carrier status of the p.Cys122Tyr *KCNJ2* gene variant.  
713 Males and females are marked with squares and circles, respectively. Mutation carriers are  
714 marked with (-/+) and non-carriers with (-/-). Uncertain mutation carriers are marked with (?)  
715 and non-affected with (N). Phenotype positive individuals are marked in black. Proband is  
716 indicated with black arrow and (P). **C.** Twelve-lead ECG of proband (II.2) at age 23, showing  
717 an episode of syncopal polymorphic ventricular tachycardia during sodium channel blocker  
718 (Mexiletine; 600mg/day) treatment combined with  $\beta$ -blocker therapy (Propranolol; 20mg/12h)  
719 **D:** ECG of the proband (II.2) showing typical Andersen-Tawil Syndrome abnormalities.  
720 Prominent U waves are marked by black arrows. Bidirectional ventricular extrasystoles are  
721 marked by red arrows. **E:** ECG from individual III.1 demonstrating genotype-phenotype  
722 segregation. Prominent U waves are marked with black arrows. Broad T wave and QTc  
723 interval prolongation is marked by a red line (510 ms).

724

725 **Figure 2. Kir2.1<sup>C122Y</sup> mice recapitulate the ATS1 patients' phenotype and increased**  
726 **susceptibility to arrhythmias. A:** Representative lead-II ECG recordings from AAV-  
727 transduced Kir2.1<sup>WT</sup> (top) and Kir2.1<sup>C122Y</sup> (bottom) mice. The record shows normal sinus  
728 rhythm with prolonged PR interval in mutant animals (N= 7 animals per group). **B:** ECG in a  
729 Kir2.1<sup>C122Y</sup> animal showing frequent premature ventricular complexes (PVCs) manifested as  
730 duplets. **C-D:** Effects of isoprenaline (ISO, 5 mg/Kg) administration on electrical conduction  
731 and QT interval in Kir2.1<sup>C122Y</sup> animals compared to basal condition (N= 7 animals per group).  
732 **E:** Representative lead-II ECG traces (top) and corresponding intracardiac recordings  
733 (bottom) before (SR; sinus rhythm), during and after intracardiac application of stimulus trains  
734 at 10 and 25 Hz under basal conditions. **E.1**, atrial stimulation in a Kir2.1<sup>WT</sup> mouse failed to  
735 induce an arrhythmia. **E.2**, atrial stimulation in a Kir2.1<sup>C122Y</sup> mouse induced a period atrial  
736 fibrillation. **E.3**, ventricular stimulation in a Kir2.1<sup>C122Y</sup> mouse induced polymorphic ventricular

737 tachycardia (PVT). **F:** Contingency plots of number of animals with arrhythmogenic response  
738 after intracardiac stimulation at baseline, and after treatment with ISO (5 mg/Kg). Each value  
739 is the mean  $\pm$  SEM (N=7-9 animals per group). Statistical analysis by two-tailed ANOVA and  
740 Student-t test. \*  $p < 0.05$ ; \*\*  $p < 0.01$ .

741

742 **Figure 3. Kir2.1<sup>C122Y</sup> cardiomyocytes preserve Kir2.1 and Nav1.5 protein trafficking, but**

743 **both proteins are reduced at the sarcolemma. A:** Confocal images of Kir2.1 and Nav1.5

744 channels in Kir2.1<sup>WT</sup> and Kir2.1<sup>C122Y</sup> cardiomyocytes. Scale bar, 10 $\mu$ m. **B:** Fluorescence

745 intensity profiles show distribution patterns for both Kir2.1 (left panel) and Nav1.5 (right panel)

746 channels in WT and Kir2.1<sup>C122Y</sup> cardiomyocytes. Note double banding for Kir2.1 indicating

747 SR expression.<sup>24</sup> **C:** Representative immunofluorescence images show co-localization of

748 Kir2.1 (green) and Nav1.5 (red) with Na<sup>+</sup>/K<sup>+</sup> ATPase (white) at the sarcolemma. Graphs show

749 percentage of co-localization with significantly reduced Nav1.5 (\*  $p < 0.05$ ; t test). Scale bar,

750 10 $\mu$ m **D:** Western blots comparing cytosolic and sarcolemmal Kir2.1 and Nav1.5 in Kir2.1<sup>WT</sup>

751 vs Kir2.1<sup>C122Y</sup> cardiomyocytes. Data were normalized using Na<sup>+</sup>/K<sup>+</sup> ATPase. **E:** Graphs show

752 western blot quantification of cytosolic and sarcolemmal Kir2.1 and Nav1.5 channels. Note

753 reduced Nav1.5 at the sarcolemma (N=4-5 animals per group) (\*  $p < 0.05$ ; two-tailed ANOVA).

754 **F:** Confocal images of classical (AP-1) and unconventional (GRASP65) trafficking routes for

755 Kir2.1 and Nav1.5. Scale bar, 10 $\mu$ m. **G:** Quantification of fluorescence intensity profiles for

756 AP-1, F-function (% nearest neighbour distances) and percentage of GRASP co-localization

757 in isolated Kir2.1<sup>WT</sup> and Kir2.1<sup>C122Y</sup> cardiomyocytes. (N=3 animals per group; n=7-9 cells). (\*

758  $p < 0.05$ ; two-tailed ANOVA). Scale bar, 10 $\mu$ m. Each value is the mean  $\pm$  SEM.

759

760 **Figure 4. Kir2.1<sup>C122Y</sup> alters electrophysiology in isolated mouse cardiomyocytes. A:**

761 Superimposed I<sub>K1</sub> current-voltage (IV) relationships for Kir2.1<sup>WT</sup> (blue) and Kir2.1<sup>C122Y</sup> (red)

762 cardiomyocytes. **B:** Superimposed I<sub>Na</sub> IV relationships for Kir2.1<sup>WT</sup> (blue) and Kir2.1<sup>C122Y</sup> (red)

763 cardiomyocytes. **C:** Representative action potential time series recorded during current-

764 clamping in an isolated Kir2.1<sup>C122Y</sup> cardiomyocyte. Note spontaneous action potentials with

765 excessively long APD generating early afterdepolarizations (EADs) and triggered activity. **D:**

766 Membrane potential bi-stability in a Kir2.1<sup>C122Y</sup> mutant with EADs appearing above -20 mV.  
767 Graph shows quantification of bi-stability events in a Kir2.1<sup>C122Y</sup> cardiomyocyte. **E**:  
768 Representative confocal image and profile of calcium transient dynamics in another isolated  
769 Kir2.1<sup>C122Y</sup> cardiomyocyte. Note amplitude bi-stability and large numbers of spontaneous  
770 calcium release events spreading throughout the cell. **F**: Left, Immunolocalization of  
771 ryanodine receptor (RyR<sub>2</sub>) and Ca<sup>2+</sup>-ATPase (SERCA) in AAV-transduced ventricular  
772 cardiomyocytes from Kir2.1<sup>WT</sup> and Kir2.1<sup>C122Y</sup> mice. Scale bar, 10µm (N=3 animals per  
773 group; n=7-8 cells). Right, western blots showing similar amounts of total protein for both  
774 (N=4 animals per group). **G**: Representative fluorescence profiles of caffeine-induced calcium  
775 release in Kir2.1<sup>WT</sup> and Kir2.1<sup>C122Y</sup> cardiomyocytes. **H**: Graphs show amplitude, Tau (Decay  
776 kinetics) and Baseline of each Ca<sup>2+</sup> transient, as well as the total area) (N=3 animals per  
777 group; n=10-17 cells). Each value is represented as the mean ± SEM. Statistical analyses  
778 were conducted using two-tailed ANOVA. \* p<0.05; \*\* p<0.01; \*\*\*\* p<0.0001.

779

780 **Figure 5. The C122Y mutation alters Kir2.1 channel conformation and PIP<sub>2</sub> binding.**

781 **A**: Topological scheme of Kir2.1 homotetramer channel indicating cysteine positions (yellow).  
782 **B**: Amino acid sequence in Kir family indicating highly conserved extracellular disulfide bond.  
783 Cys122 and Cys154 are indicated in Kir2.1 **C**: Pairwise alignment for full model (Grey,  
784 Kir2.1<sup>WT</sup>; pink, Kir2.1<sup>C122Y</sup>). **D**: Upper panel, TMscore matrix of the pairwise alignment for the  
785 full model. Values between 0-1, where 1 is the identity. RMSD matrix (middle panel) in  
786 angstroms (Å). Lower panel, Table of Gibbs free-energy values (dG) of WT and mutant  
787 homo- and heterotetramer. **E**: Docking modelling of Kir2.1-PiP<sub>2</sub> interaction in Kir2.1<sup>WT</sup>, homo-  
788 and heterotetramers of Kir2.1<sup>C122Y</sup> (see text for detailed explanation of each panel).

789

790 **Figure 6. Extracellular disulfide bond break reduces PiP<sub>2</sub>-dependent Kir2.1 regulation.**

791 **A**: Schematic representation of Kir2.1 tetramer embedded in a bilipid layer. **B**: Structure of  
792 Kir tetramer. Monomers are represented in different colors. **C**: Illustrative C122 or Y122  
793 sidechain orientation. Superposition of Kir2.1<sup>WT</sup> (grey) and two representative Kir2.1<sup>C122Y</sup>  
794 monomers (in green the most frequent Y122 orientation, in purple, the minor one). **D**:

795 Representative illustration of hydrogen bond network between Kir2.2 and PIP<sub>2</sub>. Same  
796 hydrogen bondings as in the generated homology model were tested for Kir2.1. **E**: Evolution  
797 of the C-linker during the MD: from a helix (green) to a less structured linker, as shown by a  
798 representative 2000 ns snapshot (grey). **F**: Histogram representing the average number of  
799 PIP<sub>2</sub>-Kir2.1 hydrogen bonds per residue along the 2000 ns simulation, for Kir2.1<sup>WT</sup> (blue),  
800 Kir2.1<sup>WT/C122Y</sup> (grey) and Kir2.1<sup>WT/C122Y</sup> (red). These values are the average of the three  
801 replicas and the four chains for each tetramer. **G**: Histogram representing the percentage of  
802 frames in which the  $\psi$  dihedral angle of the Pro186 is within those expected for a 3<sub>10</sub> helix ( $\psi$   
803  $=-18\pm 30^\circ$ ). For Kir2.1<sup>WT/C122Y</sup>, A and C represent the non-mutated monomers. **H**: I<sub>176</sub> and  
804 M<sub>180</sub> C $\alpha$ -C $\alpha$  distances between two opposite monomers along the 2000 ns MD. Color code  
805 on top. N=3 replicates.

806

807 **Figure 7. The C122Y mutation reduces Kir2.1-PIP<sub>2</sub> binding capacity and interaction.**

808 **A**: Diagram of Kir2.1 monomer fused to the bioluminescent protein nanoluciferase (Nluc)  
809 (adapted from Cabanos et al.<sup>25</sup>). **B**: Specific BRET signal of binding FI-PIP<sub>2</sub> to Kir2.1 WT,  
810 C122Y and R218W and competition with non-fluorescent PIP<sub>2</sub> version. Reduced binding  
811 was observed for C122Y and R218W (N=3 replicates per group; n=8-10 wells). **C**:  
812 Representative inside-out recording of I<sub>K1</sub> in the absence (black current) and the presence of  
813 25 (blue) and 50 (purple)  $\mu\text{g/ml}$  of PiP<sub>2</sub>. **D**: Normalized peak currents ( $I/I_0$ ) from -30 to +10  
814 mV show that heterozygous condition abolishes the response to increasing PIP<sub>2</sub>  
815 concentration. In contrast, in Kir2.1<sup>WT</sup>-transfected cells inward current increased  
816 progressively with PIP<sub>2</sub>. Both groups maintained an unaltered outward I<sub>K1</sub>. (n=7). Statistical  
817 analyses were conducted using two-tailed ANOVA. \* p<0.05; \*\* p<0.01; \*\*\*\* p<0.0001

818 **References**

819

820

821 1 Tawil, R. *et al.* Andersen's syndrome: potassium-sensitive periodic paralysis,  
822 ventricular ectopy, and dysmorphic features. *Ann Neurol* **35**, 326-330 (1994).  
823 [https://doi.org:10.1002/ana.410350313](https://doi.org/10.1002/ana.410350313)

824 2 Tristani-Firouzi, M. *et al.* Functional and clinical characterization of KCNJ2  
825 mutations associated with LQT7 (Andersen syndrome). *J Clin Invest* **110**, 381-388  
826 (2002). [https://doi.org:10.1172/JCI15183](https://doi.org/10.1172/JCI15183)

827 3 Plaster, N. M. *et al.* Mutations in Kir2.1 cause the developmental and episodic  
828 electrical phenotypes of Andersen's syndrome. *Cell* **105**, 511-519 (2001).  
829 [https://doi.org:S0092-8674\(01\)00342-7](https://doi.org/S0092-8674(01)00342-7) [pii]

830 4 Yoon, G. *et al.* Andersen-Tawil syndrome: prospective cohort analysis and  
831 expansion of the phenotype. *Am J Med Genet A* **140**, 312-321 (2006).  
832 [https://doi.org:10.1002/ajmg.a.31092](https://doi.org/10.1002/ajmg.a.31092)

833 5 Manuel, A. I. M. *et al.* Molecular stratification of arrhythmogenic mechanisms in  
834 the Andersen Tawil Syndrome. *Cardiovasc Res* (2022).  
835 [https://doi.org:10.1093/cvr/cvac118](https://doi.org/10.1093/cvr/cvac118)

836 6 Panama, B. K., McLerie, M. & Lopatin, A. N. Heterogeneity of IK1 in the mouse  
837 heart. *Am J Physiol Heart Circ Physiol* **293**, H3558-3567 (2007).  
838 [https://doi.org:10.1152/ajpheart.00419.2007](https://doi.org/10.1152/ajpheart.00419.2007)

839 7 Dhamoon, A. S. & Jalife, J. The inward rectifier current (IK1) controls cardiac  
840 excitability and is involved in arrhythmogenesis. *Heart Rhythm* **2**, 316-324  
841 (2005). [https://doi.org:10.1016/j.hrthm.2004.11.012](https://doi.org/10.1016/j.hrthm.2004.11.012)

842 8 Pegan, S., Arrabit, C., Slesinger, P. A. & Choe, S. Andersen's syndrome mutation  
843 effects on the structure and assembly of the cytoplasmic domains of Kir2.1.  
844 *Biochemistry* **45**, 8599-8606 (2006). [https://doi.org:10.1021/bi060653d](https://doi.org/10.1021/bi060653d)

845 9 Handklo-Jamal, R. *et al.* Andersen-Tawil Syndrome Is Associated With Impaired  
846 PIP2 Regulation of the Potassium Channel Kir2.1. *Front Pharmacol* **11**, 672  
847 (2020). [https://doi.org:10.3389/fphar.2020.00672](https://doi.org/10.3389/fphar.2020.00672)

848 10 Lopes, C. M. *et al.* Alterations in conserved Kir channel-PIP2 interactions underlie  
849 channelopathies. *Neuron* **34**, 933-944 (2002). [https://doi.org:10.1016/s0896-  
850 6273\(02\)00725-0](https://doi.org/10.1016/s0896-6273(02)00725-0)

851 11 Donaldson, M. R. *et al.* PIP2 binding residues of Kir2.1 are common targets of  
852 mutations causing Andersen syndrome. *Neurology* **60**, 1811-1816 (2003).

853 12 Cho, H. C., Tsushima, R. G., Nguyen, T. T., Guy, H. R. & Backx, P. H. Two critical  
854 cysteine residues implicated in disulfide bond formation and proper folding of  
855 Kir2.1. *Biochemistry* **39**, 4649-4657 (2000). [https://doi.org:10.1021/bi992469g](https://doi.org/10.1021/bi992469g)

856 13 Marino, S. M. & Gladyshev, V. N. Analysis and functional prediction of reactive  
857 cysteine residues. *J Biol Chem* **287**, 4419-4425 (2012).  
858 [https://doi.org:10.1074/jbc.R111.275578](https://doi.org/10.1074/jbc.R111.275578)

859 14 Garneau, L., Klein, H., Parent, L. & Sauve, R. Contribution of cytosolic cysteine  
860 residues to the gating properties of the Kir2.1 inward rectifier. *Biophys J* **84**,  
861 3717-3729 (2003). [https://doi.org:10.1016/S0006-3495\(03\)75100-5](https://doi.org/10.1016/S0006-3495(03)75100-5)

862 15 Gomez, R. *et al.* Structural basis of drugs that increase cardiac inward rectifier  
863 Kir2.1 currents. *Cardiovasc Res* **104**, 337-346 (2014).  
864 [https://doi.org:10.1093/cvr/cvu203](https://doi.org/10.1093/cvr/cvu203)

- 865 16 Caballero, R. *et al.* Flecainide increases Kir2.1 currents by interacting with  
866 cysteine 311, decreasing the polyamine-induced rectification. *Proceedings of the*  
867 *National Academy of Sciences of the United States of America* **107**, 15631-15636  
868 (2010). <https://doi.org/10.1073/pnas.1004021107>
- 869 17 Bannister, J. P., Young, B. A., Sivaprasadarao, A. & Wray, D. Conserved  
870 extracellular cysteine residues in the inwardly rectifying potassium channel  
871 Kir2.3 are required for function but not expression in the membrane. *FEBS Lett*  
872 **458**, 393-399 (1999). [https://doi.org/10.1016/s0014-5793\(99\)01096-0](https://doi.org/10.1016/s0014-5793(99)01096-0)
- 873 18 Leyland, M. L., Dart, C., Spencer, P. J., Sutcliffe, M. J. & Stanfield, P. R. The  
874 possible role of a disulphide bond in forming functional Kir2.1 potassium  
875 channels. *Pflugers Arch* **438**, 778-781 (1999).  
876 <https://doi.org/10.1007/s004249900153>
- 877 19 Fernandes, C. A. H. *et al.* Cryo-electron microscopy unveils unique structural  
878 features of the human Kir2.1 channel. *Sci Adv* **8**, eabq8489 (2022).  
879 <https://doi.org/10.1126/sciadv.abq8489>
- 880 20 Xiao, X., Li, J. & Samulski, R. J. Production of high-titer recombinant adeno-  
881 associated virus vectors in the absence of helper adenovirus. *J Virol* **72**, 2224-  
882 2232 (1998). <https://doi.org/10.1128/JVI.72.3.2224-2232.1998>
- 883 21 Hauswirth, W. W., Lewin, A. S., Zolotukhin, S. & Muzyczka, N. Production and  
884 purification of recombinant adeno-associated virus. *Methods Enzymol* **316**, 743-  
885 761 (2000). [https://doi.org/10.1016/s0076-6879\(00\)16760-6](https://doi.org/10.1016/s0076-6879(00)16760-6)
- 886 22 Cruz, F. M. *et al.* Exercise triggers ARVC phenotype in mice expressing a disease-  
887 causing mutated version of human plakophilin-2. *J Am Coll Cardiol* **65**, 1438-1450  
888 (2015). [https://doi.org/S0735-1097\(15\)00445-3](https://doi.org/S0735-1097(15)00445-3) [pii]  
889 10.1016/j.jacc.2015.01.045
- 890 23 Bao, Y. *et al.* Scn2b Deletion in Mice Results in Ventricular and Atrial Arrhythmias.  
891 *Circ Arrhythm Electrophysiol* **9** (2016).  
892 <https://doi.org/10.1161/CIRCEP.116.003923>
- 893 24 Macías, Á. *et al.* Kir2.1 dysfunction at the sarcolemma and the sarcoplasmic  
894 reticulum causes arrhythmias in a mouse model of Andersen–Tawil syndrome  
895 type 1. *Nature Cardiovascular Research* (2022). <https://doi.org/10.1038/s44161-022-00145-2>
- 896
- 897 25 Cabanos, C., Wang, M., Han, X. & Hansen, S. B. A Soluble Fluorescent Binding  
898 Assay Reveals PIP2 Antagonism of TREK-1 Channels. *Cell Rep* **20**, 1287-1294  
899 (2017). <https://doi.org/10.1016/j.celrep.2017.07.034>
- 900 26 Semenov, I. *et al.* Excitation and injury of adult ventricular cardiomyocytes by  
901 nano- to millisecond electric shocks. *Sci Rep* **8**, 8233 (2018).  
902 <https://doi.org/10.1038/s41598-018-26521-2>
- 903 27 Brette, F., Despa, S., Bers, D. M. & Orchard, C. H. Spatiotemporal characteristics  
904 of SR Ca(2+) uptake and release in detubulated rat ventricular myocytes. *J Mol*  
905 *Cell Cardiol* **39**, 804-812 (2005). <https://doi.org/10.1016/j.yjmcc.2005.08.005>
- 906 28 Macias, A. *et al.* Paclitaxel mitigates structural alterations and cardiac conduction  
907 system defects in a mouse model of Hutchinson-Gilford progeria syndrome.  
908 *Cardiovasc Res* (2021). <https://doi.org/10.1093/cvr/cvab055>
- 909 29 Schram, G., Melnyk, P., Pourrier, M., Wang, Z. & Nattel, S. Kir2.4 and Kir2.1 K(+)  
910 channel subunits co-assemble: a potential new contributor to inward rectifier

- 911 current heterogeneity. *J Physiol* **544**, 337-349 (2002).  
912 <https://doi.org/10.1113/jphysiol.2002.026047>
- 913 30 Ballester, L. Y. *et al.* Trafficking-competent and trafficking-defective KCNJ2  
914 mutations in Andersen syndrome. *Hum Mutat* **27**, 388 (2006).  
915 <https://doi.org/10.1002/humu.9418>
- 916 31 Haruna, Y. *et al.* Genotype-phenotype correlations of KCNJ2 mutations in  
917 Japanese patients with Andersen-Tawil syndrome. *Hum Mutat* **28**, 208 (2007).  
918 <https://doi.org/10.1002/humu.9483>
- 919 32 Ma, D. *et al.* Golgi export of the Kir2.1 channel is driven by a trafficking signal  
920 located within its tertiary structure. *Cell* **145**, 1102-1115 (2011).  
921 [https://doi.org/S0092-8674\(11\)00649-0](https://doi.org/S0092-8674(11)00649-0) [pii]  
922 10.1016/j.cell.2011.06.007
- 923 33 Perez-Hernandez, M. *et al.* Brugada syndrome trafficking-defective Nav1.5  
924 channels can trap cardiac Kir2.1/2.2 channels. *JCI Insight* **3** (2018).  
925 <https://doi.org/10.1172/jci.insight.96291>
- 926 34 Pini, J. *et al.* Osteogenic and Chondrogenic Master Genes Expression Is  
927 Dependent on the Kir2.1 Potassium Channel Through the Bone Morphogenetic  
928 Protein Pathway. *J Bone Miner Res* **33**, 1826-1841 (2018).  
929 <https://doi.org/10.1002/jbmr.3474>
- 930 35 Hansen, S. B., Tao, X. & MacKinnon, R. Structural basis of PIP2 activation of the  
931 classical inward rectifier K<sup>+</sup> channel Kir2.2. *Nature* **477**, 495-498 (2011).  
932 <https://doi.org/10.1038/nature10370>
- 933 36 Lee, S. J. *et al.* Structural basis of control of inward rectifier Kir2 channel gating  
934 by bulk anionic phospholipids. *J Gen Physiol* **148**, 227-237 (2016).  
935 <https://doi.org/10.1085/jgp.201611616>
- 936 37 Zangerl-Plessl, E. M. *et al.* Atomistic basis of opening and conduction in  
937 mammalian inward rectifier potassium (Kir2.2) channels. *J Gen Physiol* **152**  
938 (2020). <https://doi.org/10.1085/jgp.201912422>
- 939 38 Fagnen, C. *et al.* New Structural insights into Kir channel gating from molecular  
940 simulations, HDX-MS and functional studies. *Sci Rep* **10**, 8392 (2020).  
941 <https://doi.org/10.1038/s41598-020-65246-z>
- 942 39 Gadsby, D. C. & Cranefield, P. F. Two levels of resting potential in cardiac Purkinje  
943 fibers. *J Gen Physiol* **70**, 725-746 (1977). <https://doi.org/10.1085/jgp.70.6.725>
- 944 40 Suh, B. C. & Hille, B. PIP2 is a necessary cofactor for ion channel function: how  
945 and why? *Annu Rev Biophys* **37**, 175-195 (2008).  
946 <https://doi.org/10.1146/annurev.biophys.37.032807.125859>
- 947 41 Soom, M. *et al.* Multiple PIP2 binding sites in Kir2.1 inwardly rectifying potassium  
948 channels. *FEBS Lett* **490**, 49-53 (2001). [https://doi.org/10.1016/s0014-5793\(01\)02136-6](https://doi.org/10.1016/s0014-5793(01)02136-6)
- 949 42 Tully, I. *et al.* Rarity and phenotypic heterogeneity provide challenges in the  
950 diagnosis of Andersen-Tawil syndrome: Two cases presenting with ECGs  
951 mimicking catecholaminergic polymorphic ventricular tachycardia (CPVT). *Int J*  
952 *Cardiol* **201**, 473-475 (2015). <https://doi.org/10.1016/j.ijcard.2015.07.069>
- 953 43 Kukla, P., Biernacka, E. K., Baranchuk, A., Jastrzebski, M. & Jagodzinska, M.  
954 Electrocardiogram in Andersen-Tawil syndrome. New electrocardiographic  
955 criteria for diagnosis of type-1 Andersen-Tawil syndrome. *Curr Cardiol Rev* **10**,  
956 222-228 (2014).  
957



- 958 44 Bannister, M. L., MacLeod, K. T. & George, C. H. Moving in the right direction:  
959 elucidating the mechanisms of interaction between flecainide and the cardiac  
960 ryanodine receptor. *Br J Pharmacol* **179**, 2558-2563 (2022).  
961 <https://doi.org/10.1111/bph.15718>
- 962 45 Zsolnay, V., Fill, M. & Gillespie, D. Sarcoplasmic Reticulum Ca(2+) Release Uses a  
963 Cascading Network of Intra-SR and Channel Countercurrents. *Biophys J* **114**, 462-  
964 473 (2018). <https://doi.org/10.1016/j.bpj.2017.11.3775>
- 965 46 Katan, M. & Cockcroft, S. Phosphatidylinositol(4,5)bisphosphate: diverse  
966 functions at the plasma membrane. *Essays Biochem* **64**, 513-531 (2020).  
967 <https://doi.org/10.1042/EBC20200041>
- 968 47 Abriel, H., Rougier, J. S. & Jalife, J. Ion channel macromolecular complexes in  
969 cardiomyocytes: roles in sudden cardiac death. *Circ Res* **116**, 1971-1988 (2015).  
970 <https://doi.org/10.1161/CIRCRESAHA.116.305017>
- 971 48 Meadows, L. S. & Isom, L. L. Sodium channels as macromolecular complexes:  
972 Implications for inherited arrhythmia syndromes. *Cardiovasc Res* **67**, 448-458  
973 (2005).
- 974 49 Willis, B. C., Ponce-Balbuena, D. & Jalife, J. Protein assemblies of sodium and  
975 inward rectifier potassium channels control cardiac excitability and  
976 arrhythmogenesis. *Am J Physiol Heart Circ Physiol* **308**, H1463-1473 (2015).  
977 <https://doi.org/10.1152/ajpheart.00176.2015>
- 978 50 Siegel, M. R. & Sisler, H. D. Inhibition of Protein Synthesis in Vitro by  
979 Cycloheximide. *Nature* **200**, 675-676 (1963). <https://doi.org/10.1038/200675a0>
- 980 51 van Bemmelen, M. X. *et al.* Cardiac voltage-gated sodium channel Nav1.5 is  
981 regulated by Nedd4-2 mediated ubiquitination. *Circ Res* **95**, 284-291 (2004).  
982 <https://doi.org/10.1161/01.RES.0000136816.05109.89>
- 983 52 Luo, L. *et al.* Calcium-dependent Nedd4-2 upregulation mediates degradation of  
984 the cardiac sodium channel Nav1.5: implications for heart failure. *Acta Physiol*  
985 (*Oxf*) **221**, 44-58 (2017). <https://doi.org/10.1111/apha.12872>  
986













